

Abstract of the Disclosure

The present invention is a pharmaceutical composition for polypeptides which are not stably soluble. A preferred polypeptide is monomeric insulin and a preferred formulation consists of a TRIS-phosphate combination buffer, zinc; a phenolic preservative and an isotonicity agent such as glycerol.

0000027 8E2E260

"Express Mail" mailing label number 0540750343 US  
Date of Deposit DECEMBER 8, 2020  
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231.  
• SUNE M. O'NEILL  
(printed name)  
[Signature]  
(Signature)